A Phase 3 interventional study of Ramucirumab and Capecitabine in Metastatic Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 135 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-26.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant has:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m\^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m\^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m\^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
Drug: Ramucirumab · Drug: Capecitabine · Drug: Cisplatin · Drug: Fluorouracil
Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m\^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m\^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m\^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
Drug: Capecitabine · Drug: Cisplatin · Drug: Placebo · Drug: Fluorouracil
Administered IV
Also known as: LY3009806, IMC-1121B, Cyramza
Administered orally
Administered IV
Administered IV
Administered IV
Progression-free Survival (PFS)
PFS time was measured from the date of randomization to the date of radiographic(rgr) documentation of progression(by RECIST v.1.1) or the date of death due to any cause, whichever was earlier.If a participant did not have a complete baseline tumor assessment,then the PFS time was censored at the randomization date.If a participant was not known to have died or have rgr documented progression as of the data cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. If death or progressive disease(PD) occurred after 2 or more consecutive missing rgr visits,censoring occurred at the date of the last rgr visit prior to the missed visits.If death or PD occurred after postdiscontinuation(pdis) systemic anticancer therapy,censoring occurred at the date of last rgr visit prior to the start of pdis systemic anticancer therapy. PD was defined according to RECIST v.1.1.
Time frame: Randomization to Radiological Disease Progression or Death from Any Cause (Up to 26 Months)
Overall Survival (OS)
OS was time from the date of randomization to the date of death from any cause. If the participant was alive at the cutoff for analysis (or was lost to follow-up), OS data were censored for analysis on the last date the participant was known to be alive.
Time frame: Randomization to Death from Any Cause (Up To 30 Months)
Progression- Free Survival 2 (PFS2)
PFS2 was defined as the time from the date of randomization to second disease progression (defined as objective radiological or symptomatic progression), or death of any cause, whichever occurs first. Participants alive and for whom a second disease progression has not been observed (including participants who did not receive any additional systemic anticancer treatments) were censored at the last time known to be alive and without second disease progression. The second progression refers to disease progression on or after additional systemic anticancer therapy, regardless if any earlier progression is observed or not(e.g. at the end of study treatment). It is assessed by investigator based on overall clinical evaluation, not limited to RECIST.
Time frame: Randomization to Second Radiological or Symptomatic Disease Progression After the Start of Additional Systemic Anticancer Treatment or Death from Any Cause (Up To 26 Months)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1).Target lesions - CR: Disappearance of all lesions; any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum. PD: At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions - CR: Disappearance of all lesions and normalization of tumor marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).ORR calculated as:(sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.
Time frame: Randomization to Disease Progression (Up To 26 Months)
Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])
DCR was the percentage of participants with a best overall response of CR, PR, or SD as per Response using RECIST v1.1 criteria. Target lesions - CR: Disappearance of all lesions; any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum. Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non target lesions - CR: Disappearance of all lesions and normalization of tumor marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).
Time frame: Randomization to Disease Progression (Up To 26 Months)
Time to Progression (TTP)
TTP was time from the date of randomization to the date of radiographic progression (according to RECIST v.1.1). If a participant died due to any reason without radiographic progression, TTP is censored at the last adequate tumor assessment. Target lesions: Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions: PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).
Time frame: Randomization to Disease Progression (Up To 24 Months)
Duration of Response (DoR)
Participants achieved an objective response if they had a best overall response of CR or PR.Target lesions- CR:Disappearance of all lesions;any pathological lymph nodes must have reduction in short axis to \<10 mm.PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum.PD: At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study(the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s).Non target lesions - CR: Disappearance of all lesions and normalization of tumour marker levels;all lymph nodes must be non-pathological in size. Non-CR/Non-PD:Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels.PD:Unequivocal progression of existing lesions or the appearance of new lesion(s).If a participant was not known to have died or have radiographically documented PD as of the data inclusion cutoff date,DOR was censored at the date of the last adequate tumor assessment.
Time frame: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 26 Months)
Time to Deterioration in Quality of Life (QoL) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status/ QoL Scale
Time to sustained deterioration was defined as time from randomization to first worsening in QoL with no subsequent non-worsened assessment. Worsening in global health status/QoL was defined as a decrease of ≥10 points on a 100-point scale. If a participant did not report worsening, time to sustained deterioration was censored at date of last non-worsened assessment.
Time frame: Randomization, First worsening in QoL (Up To 26 Months)
Change in Health Status on the EuroQol 5-Dimensions 5-Level Instrument (EQ-5D- 5L)
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which were anchored on a scale of 0 to 1 with a higher score representing better health status. Additionally, current health status was assessed on a visual analogue scale (VAS) ranging from 0 to 100 with a higher score representing better health status.
Time frame: Randomization, 30 Days After Treatment Discontinuation (Up To 5 Months)
Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
The time from the date of randomization to the first date observing ECOG PS ≥2 (that is, deterioration from baseline status of 0 or 1). Participants without PS deterioration were censored at their last documented assessments of 0 or 1. ECOG Performance Status: 2- Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3 -Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4 -Completely disabled. Cannot carry on any selfcare.Totally confined to bed or chair,5- Dead.
Time frame: Randomization to ECOG PS ≥2 (Up To 26 Months)
Number of Participants With Anti-Ramucirumab Antibodies
Participants who developed treatment-emergent antibody responses to Ramucirumab postbaseline.
Time frame: Predose Cycle 1 through 30 Days After Treatment Discontinuation (Up To 24 Months)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Ramucirumab
Pharmacokinetics (PK): Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Ramucirumab
Time frame: Cycle 1 Day 1: 1 hour (hr) end of infusion (EOI), Cycle 3 Day 1: 1hr EOI, Cycle 9 Day 1: 1 hr EOI
PK: Minimum Concentration (Cmin) of Ramucirumab
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
Time frame: Cycle 1 Day 1: 1 hour (hr) end of infusion (EOI), Cycle 3 Day 1: 1hr EOI, Cycle 9 Day 1: 1 hr EOI
| Milestone | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Started | 326 | 319 |
| Received at least one dose of study drug | 323 | 315 |
| Completed | 314 | 303 |
| Not completed | 12 | 16 |
| Withdrew: Lost to follow-up | 9 | 14 |
| Withdrew: Withdrawal by subject | 3 | 2 |
PFS time was measured from the date of randomization to the date of radiographic(rgr) documentation of progression(by RECIST v.1.1) or the date of death due to any cause, whichever was earlier.If a participant did not have a complete baseline tumor assessment,then the PFS time was censored at the randomization date.If a participant was not known to have died or have rgr documented progression as of the data cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. If death or progressive disease(PD) occurred after 2 or more consecutive missing rgr visits,censoring occurred at the date of the last rgr visit prior to the missed visits.If death or PD occurred after postdiscontinuation(pdis) systemic anticancer therapy,censoring occurred at the date of last rgr visit prior to the start of pdis systemic anticancer therapy. PD was defined according to RECIST v.1.1.
| months | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Progression-free Survival (PFS) | 5.72 (5.45 to 6.51) | 5.39 (4.47 to 5.72) |
OS was time from the date of randomization to the date of death from any cause. If the participant was alive at the cutoff for analysis (or was lost to follow-up), OS data were censored for analysis on the last date the participant was known to be alive.
| months | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Overall Survival (OS) | 11.17 (9.92 to 11.93) | 10.74 (9.53 to 11.89) |
PFS2 was defined as the time from the date of randomization to second disease progression (defined as objective radiological or symptomatic progression), or death of any cause, whichever occurs first. Participants alive and for whom a second disease progression has not been observed (including participants who did not receive any additional systemic anticancer treatments) were censored at the last time known to be alive and without second disease progression. The second progression refers to disease progression on or after additional systemic anticancer therapy, regardless if any earlier progression is observed or not(e.g. at the end of study treatment). It is assessed by investigator based on overall clinical evaluation, not limited to RECIST.
| months | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Progression- Free Survival 2 (PFS2) | 10.18 (9.03 to 10.84) | 9.20 (8.34 to 9.99) |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1).Target lesions - CR: Disappearance of all lesions; any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum. PD: At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions - CR: Disappearance of all lesions and normalization of tumor marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).ORR calculated as:(sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.
| percentage of participants | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 41.1 (35.8 to 46.4) | 36.4 (31.1 to 41.6) |
DCR was the percentage of participants with a best overall response of CR, PR, or SD as per Response using RECIST v1.1 criteria. Target lesions - CR: Disappearance of all lesions; any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum. Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non target lesions - CR: Disappearance of all lesions and normalization of tumor marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).
| percentage of participants | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) | 81.9 (77.7 to 86.1) | 76.5 (71.8 to 81.1) |
TTP was time from the date of randomization to the date of radiographic progression (according to RECIST v.1.1). If a participant died due to any reason without radiographic progression, TTP is censored at the last adequate tumor assessment. Target lesions: Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions: PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).
| months | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Time to Progression (TTP) | 6.77 (5.88 to 7.66) | 5.78 (5.55 to 6.37) |
Participants achieved an objective response if they had a best overall response of CR or PR.Target lesions- CR:Disappearance of all lesions;any pathological lymph nodes must have reduction in short axis to \<10 mm.PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum.PD: At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study(the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s).Non target lesions - CR: Disappearance of all lesions and normalization of tumour marker levels;all lymph nodes must be non-pathological in size. Non-CR/Non-PD:Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels.PD:Unequivocal progression of existing lesions or the appearance of new lesion(s).If a participant was not known to have died or have radiographically documented PD as of the data inclusion cutoff date,DOR was censored at the date of the last adequate tumor assessment.
| months | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Duration of Response (DoR) | 5.72 (5.09 to 6.34) | 4.27 (3.88 to 4.90) |
Time to sustained deterioration was defined as time from randomization to first worsening in QoL with no subsequent non-worsened assessment. Worsening in global health status/QoL was defined as a decrease of ≥10 points on a 100-point scale. If a participant did not report worsening, time to sustained deterioration was censored at date of last non-worsened assessment.
| months | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Time to Deterioration in Quality of Life (QoL) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status/ QoL Scale | 9.00 (8.08 to 12.58) | 9.46 (6.74 to 11.99) |
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which were anchored on a scale of 0 to 1 with a higher score representing better health status. Additionally, current health status was assessed on a visual analogue scale (VAS) ranging from 0 to 100 with a higher score representing better health status.
| units on a scale | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| EQ-5D index | -0.008 ± 0.148 | -0.010 ± 0.157 |
| EQ-5D VAS | 0.8 ± 18.56 | 1.5 ± 20.33 |
The time from the date of randomization to the first date observing ECOG PS ≥2 (that is, deterioration from baseline status of 0 or 1). Participants without PS deterioration were censored at their last documented assessments of 0 or 1. ECOG Performance Status: 2- Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3 -Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4 -Completely disabled. Cannot carry on any selfcare.Totally confined to bed or chair,5- Dead.
| months | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) | NA (12.2 to NA) | NA (NA to NA) |
Participants who developed treatment-emergent antibody responses to Ramucirumab postbaseline.
| Participants | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine |
|---|---|---|
| Number of Participants With Anti-Ramucirumab Antibodies | 4 | 5 |
Pharmacokinetics (PK): Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Ramucirumab
| Microgram/milliliter (µg/mL) | Ramucirumab + Cisplatin + Capecitabine |
|---|---|
| Cycle 1, Day 1 | 133 ± 31 |
| Cycle 3, Day 1 | 173 ± 35 |
| Cycle 9, Day 1 | 169 ± 60 |
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
| µg/mL | Ramucirumab + Cisplatin + Capecitabine |
|---|---|
| Cycle 1, Day 8 | 40.7 ± 35 |
| Cycle 2, Day 1 | 35.7 ± 56 |
| Cycle 3, Day 1 | 51.2 ± 47 |
| Cycle 5, Day 1 | 69.7 ± 52 |
| Cycle 9, Day 1 | 77.6 ± 98 |
Collected over Baseline Up To 5.6 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY3009806+Capecitabine+Cisplatin | — | 161/323 (49.8%) | 315/323 (97.5%) |
| Placebo+Capecitabine+Cisplatin | — | 150/315 (47.6%) | 304/315 (96.5%) |
| Event | LY3009806+Capecitabine+Cisplatin | Placebo+Capecitabine+Cisplatin |
|---|---|---|
| VomitingGastrointestinal disorders | 14/323 | 22/315 |
| DiarrhoeaGastrointestinal disorders | 11/323 | 19/315 |
| Abdominal painGastrointestinal disorders | 13/323 | 7/315 |
| PyrexiaGeneral disorders | 2/323 | 12/315 |
| AnaemiaBlood and lymphatic system disorders | 11/323 | 11/315 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/323 | 11/315 |
| Acute kidney injuryRenal and urinary disorders | 10/323 | 8/315 |
| DehydrationMetabolism and nutrition disorders | 7/323 | 9/315 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/323 | 9/315 |
| Gastric perforationGastrointestinal disorders | 9/323 | 1/315 |
| Event | LY3009806+Capecitabine+Cisplatin | Placebo+Capecitabine+Cisplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 205/323 | 186/315 |
| FatigueGeneral disorders | 153/323 | 145/315 |
| VomitingGastrointestinal disorders | 134/323 | 117/315 |
| Decreased appetiteMetabolism and nutrition disorders | 130/323 | 100/315 |
| AnaemiaBlood and lymphatic system disorders | 104/323 | 114/315 |
| DiarrhoeaGastrointestinal disorders | 108/323 | 107/315 |
| ConstipationGastrointestinal disorders | 104/323 | 78/315 |
| Neutrophil count decreasedInvestigations | 103/323 | 92/315 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 99/323 | 63/315 |
| NeutropeniaBlood and lymphatic system disorders | 71/323 | 74/315 |
All randomized participants.
| Age, Continuous(years) | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine | Total |
|---|---|---|---|
| Mean | 58.9 ± 11.6 | 60.1 ± 11.8 | 59.5 ± 11.7 |
| Sex: Female, Male(Participants) | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine | Total |
|---|---|---|---|
| Female | 112 | 104 | 216 |
| Male | 214 | 215 | 429 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine | Total |
|---|---|---|---|
| Hispanic or Latino | 67 | 62 | 129 |
| Not Hispanic or Latino | 227 | 245 | 472 |
| Unknown or Not Reported | 32 | 12 | 44 |
| Race (NIH/OMB)(Participants) | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 12 | 11 | 23 |
| Asian | 38 | 31 | 69 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 2 | 3 | 5 |
| White | 256 | 264 | 520 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 17 | 10 | 27 |
| Region of Enrollment(Participants) | Ramucirumab + Cisplatin + Capecitabine | Placebo + Cisplatin + Capecitabine | Total |
|---|---|---|---|
| Puerto Rico | 1 | 1 | 2 |
| Argentina | 21 | 22 | 43 |
| Hungary | 15 | 16 | 31 |
| United States | 42 | 31 | 73 |
| Czechia | 11 | 8 | 19 |
| Japan | 32 | 28 | 60 |
| United Kingdom | 20 | 22 | 42 |
| Russia | 25 | 25 | 50 |
| Spain | 10 | 13 | 23 |
| Canada | 10 | 6 | 16 |
| Netherlands | 4 | 7 | 11 |
| Belgium | 8 | 5 | 13 |
| Finland | 3 | 5 | 8 |
| Denmark | 12 | 3 | 15 |
| Poland | 8 | 10 | 18 |
| Italy | 28 | 45 | 73 |
| Mexico | 26 | 26 | 52 |
| Israel | 11 | 12 | 23 |
| France | 19 | 21 | 40 |
| Germany | 20 | 13 | 33 |
Showing the first 100 of 135 sites across 20 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2015 to primary completion in Jan 2017, 23 months.
Results were first posted in May 2018, 1 year 3 months after primary completion. A results delay was requested in Oct 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab